Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1143 in Ovarian Cancer
Debiopharm today announced the start of a phase II clinical trial for Debio 1143 in combination with standard of care Carboplatin and Paclitaxel in Epithelial Ovarian Cancer
OTE0001
FDA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer
Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announced that the FDA Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation …
OTE0002
Debiopharm International SA Announces Presentation at AACR of Non-clinical Data Relating to its Targeted Investigational Compound Debio 1347
CH5183284, a Selective FGFR 1,2,3 Inhibitor
OTE0002
Debiopharm International SA to Present the Latest Findings on Debio 1450 at ECCMID
Debiopharm will be present at ECCMID in Amsterdam to share new data supporting the clinical development of its first in class Staphylococcus-selective antibiotic Debio 1450
OTE0001
Debiopharm International SA Has Won Its Patent Infringement Suit for Elplat® Against Nippon Kayaku Co., Ltd.
Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company today announces that the Tokyo District Court granted Debiopharm an overall victory for …
OTE0002
Debiopharm International SA and EORTC Announce a Collaboration to Investigate Triptorelin for Treatment of Salivary Gland Cancers
Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced a collaboration in order to supply triptorelin pamoate 3.75 mg 1-month …
OTE0005
Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce Their US Commercialization Partnership for Triptorelin in Central Precocious Puberty
Arbor Pharmaceuticals to commercialize triptorelin in sustained-release formulation for the orphan indication central precocious puberty
OTE0003
EMA Grants Orphan Drug Designation to Debiopharm International SA's IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer
Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced that the European Medicines Agency (EMA) granted Orphan Drug …
OTE0002
United Laboratories Inc. and Debiopharm International SA Announce the Launch of Pamorelin® LA in the Philippines
Pamorelin® one-, three- and six-month dosing option now available to patients in the Philippines
OTE0001
Debiopharm International SA's Partner Yakult Honsha Co, Ltd. Announces Elplat® Approbation in Gastric Cancer in Japan
Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, is proud to congratulate its partner Yakult's commitment in obtaining approval for a …
OTE0001
Debiopharm International SA Presents Positive Preliminary Results From Phase 1 Trials in the Development of the IAP Inhibitor Debio 1143 at the 27th EORTC-NCI-AACR Symposium in Boston
Recommended Dose reached and early signs of efficacy seen
OTE0002
Die Japanische Krebsgesellschaft und die Debiopharm Group geben die Gewinner des JCA-Mauvernay Awards 2015 bekannt
Der "JCA-Mauvernay Award 2015" geht an Dr. Yutaka Kondo und Dr. Junko Takita
OTS0015
Debiopharm International SA und Solid Biosciences, LLC, kündigen Partnerschaft an, um die Anwendung von Alisporivir (Debio 025) bei Muskeldystrophie zu erforschen
Debiopharm startet zusammen mit Solid Biosciences, einem auf DMD spezialisiertes Biotech-Unternehmen, präklinische Tierstudien für Muskeldystrophie Typ Duchenne (DMD).
OTS0020
Debiopharm International SA Acquires FibroTrap Sample Processing Technology from Spinomix
Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, and Spinomix, a Swiss technology platform company providing innovative sample …
OTE0005
Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1450 in Staphylococcal Skin Infections
One year after the initiation of Phase I, Debiopharm announced the start of clinical phase II for Debio 1450 in ABSSSI and presentation of new data at ECCMID
OTE0001
